Champerty is a doctrine of law which forbids certain situations in which a third party pays litigation expenses in return for a share in any proceeds.  It’s an interesting idea for...

This article recently appeared in Oxford’s Journal of Intellectual Property Law & Practice. In essence, in a long-awaited decision, the Australian High Court reviewed several key questions pertaining to patent validity...

Here are my top 5 reasons not to settle IP litigation from the IP owner’s perspective: The other side are not even close to offering a reasonable deal. A state sanctioned...

‘Warfighting’ the US Marines book of strategy, defines ‘Friction’ as – “the force that resists all action. It makes the simple difficult and the difficult seemingly impossible.”The very essence of war...

The Recording Industry Association ofAmerica (RIAA) recently obtained a $220,000 verdict in the first of their currently pending 26,000 law suits against individuals alleging copyright infringement by file sharing.  The case...

Livemint reported late last week that the association of innovator pharmaceutical companies in India (‘OPPI‘), has recently reiterated its demand for removal of the pre-grant patent opposition provisions from India’s Patent...

There’s a common strategic issue for generic pharmaceuticla manufacturers as to whether they should obtain a win in court before launching their product. The risks are (a) an injunction and (b)...

Thanks to Patent Docs blog for pointing out that on Monday this week Nucleonics sought en banc review of the CAFC decision which held that it no longer had standing to...

Russia and the USA came first and second in IPKat’s recent poll asking readers to nominate the country in which they would least like to litigate an IP case. (China came...

In an update to the Lipitor Scorecard – mixed success for Ranbaxy in Spain today, but no ealier launch.   (This comes after Ranbaxy’s recent success and launch in Norway.) The...